Genetic and functional analyses implicate microRNA 499A in bipolar disorder development

• Verfasst von: Tielke, Aileen [VerfasserIn]
• Verfasst von: Streit, Fabian [VerfasserIn]
• Verfasst von: Sirignano, Lea [VerfasserIn]
• Verfasst von: Schulze, Thomas Gerd [VerfasserIn]
• Verfasst von: Witt, Stephanie [VerfasserIn]
• Verfasst von: Rietschel, Marcella [VerfasserIn]
• Titel: Genetic and functional analyses implicate microRNA 499A in bipolar disorder development
• Verf.angabe: Aileen Tielke, Helena Martins, Michael A. Pelzl, Anna Maaser-Hecker, Friederike S. David, Céline S. Reinbold, Fabian Streit, Lea Sirignano, Markus Schwarz, Helmut Vedder, Jutta Kammerer-Ciernioch, Margot Albus, Margitta Borrmann-Hassenbach, Martin Hautzinger, Karola Hünten, Franziska Degenhardt, Sascha B. Fischer, Eva C. Beins, Stefan Herms, Per Hoffmann, Thomas G. Schulze, Stephanie H. Witt, Marcella Rietschel, Sven Cichon, Markus M. Nöthen, Gerhard Schratt and Andreas J. Forstner
• E-Jahr: 2022
• Jahr: 07 October 2022
• Umfang: 10 S.
• Illustrationen: Illustrationen
• Fussnoten: Gesehen am 01.02.2023
• Titel Quelle: Enthalten in: Translational Psychiatry
• Ort Quelle: London : Nature Publishing Group, 2011
• Jahr Quelle: 2022
• Band/Heft Quelle: 12(2022) vom: Okt., Artikel-ID 437, Seite 1-10
• ISSN Quelle: 2158-3188
• DOI: doi:10.1038/s41398-022-02176-6
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Bipolar disorder
• Sach-SW: Genetics
• K10plus-PPN: 183290704X

Abstract

Bipolar disorder (BD) is a complex mood disorder with a strong genetic component. Recent studies suggest that microRNAs contribute to psychiatric disorder development. In BD, specific candidate microRNAs have been implicated, in particular miR-137, miR-499a, miR-708, miR-1908 and miR-2113. The aim of the present study was to determine the contribution of these five microRNAs to BD development. For this purpose, we performed: (i) gene-based tests of the five microRNA coding genes, using data from a large genome-wide association study of BD; (ii) gene-set analyses of predicted, brain-expressed target genes of the five microRNAs; (iii) resequencing of the five microRNA coding genes in 960 BD patients and 960 controls and (iv) in silico and functional studies for selected variants. Gene-based tests revealed a significant association with BD for MIR499A, MIR708, MIR1908 and MIR2113. Gene-set analyses revealed a significant enrichment of BD associations in the brain-expressed target genes of miR-137 and miR-499a-5p. Resequencing identified 32 distinct rare variants (minor allele frequency < 1%), all of which showed a non-significant numerical overrepresentation in BD patients compared to controls (p = 0.214). Seven rare variants were identified in the predicted stem-loop sequences of MIR499A and MIR2113. These included rs142927919 in MIR2113 (pnom = 0.331) and rs140486571 in MIR499A (pnom = 0.297). In silico analyses predicted that rs140486571 might alter the miR-499a secondary structure. Functional analyses showed that rs140486571 significantly affects miR-499a processing and expression. Our results suggest that MIR499A dysregulation might contribute to BD development. Further research is warranted to elucidate the contribution of the MIR499A regulated network to BD susceptibility.